AG
NGM

Algert Global’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Algert Global’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-37,390
Closed -$40K – 1300
2023
Q3 		$40K Sell
37,390
-99,860
-73% -$207K ﹤0.01% 1075
2023
Q2 		$355K Sell
137,250
-15,010
-10% -$53.5K 0.02% 881
2023
Q1 		$621K Buy
152,260
+78,370
+106% +$362K 0.03% 773
2022
Q4 		$371K Sell
73,890
-3,950
-5% -$24.8K 0.02% 886
2022
Q3 		$1.02M Buy
77,840
+5,877
+8% +$89K 0.06% 534
2022
Q2 		$923K Buy
71,963
+43,050
+149% +$596K 0.07% 517
2022
Q1 		$441K Buy
28,913
+8,267
+40% +$129K 0.03% 854
2021
Q4 		$366K Buy
+20,646
New +$396K 0.05% 660

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Algert Global's NGM Position: Q4 2023 in Review

Algert Global sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2023, closing a stake of 37,390 shares — an estimated $40K sold.

Algert Global first reported a position in NGM in Q4 2021 and held it in 8 quarters. The position peaked at $1.02M in Q3 2022. 83 funds tracked by Wall St. Rank hold NGM as of Q4 2023.

  • Algert Global reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Algert Global sold 37,390 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $40K.
  • Algert Global first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
  • Algert Global's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.02M in Q3 2022.
  • 83 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Algert Global's 13F filing for Q4 2023, filed 14 Feb 2024.